DNA fingerprinting could reveal hidden cancer origins
NCT ID NCT06140992
First seen Apr 23, 2026 · Last updated Jun 21, 2026 · Updated 10 times
Summary
This study is testing a new tool that uses DNA methylation patterns to figure out where a cancer started when doctors can't find the original tumor. Researchers will analyze tissue samples from 120 people with cancer of unknown primary. If it works, this approach could help guide more personalized treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNKNOWN PRIMARY TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNA methylation classifier (PaCIFiC-CUP)
What this could lead to
If successful, this could provide a new way to pinpoint the origin of hard-to-identify cancers, helping doctors choose more targeted treatments.
What could go wrong
This is an early-stage study with only 120 participants, so results may not apply to everyone. The model might not work for all cancer types or could be inaccurate.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.